

Figure 1


(±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione



(±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione.



(±)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



(±)-cis-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione






Figure 2

(-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



LC_{50} = 0.62 μM

(+)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



LC_{50} = 4.1 μM

Figure 3





(±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione
(±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione
μM
Control
0.05
0.5
10
0.05
0.5
10

Figure 4



Panel A



Panel B

A= (-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

B= (+)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

Figure 5




Figure 6




Figure 7





Control
(-)-Trans 200mg/kg po qd
Mean Tumor Volume, mm3
1400
1200
1000
800
600
400
200
0
0
8
11
15
18
22
25
32
37
39
44
47
51
Days Post Innoculation

Figure 8




Panel A




Panel B

Figures 9A and 9B




Panel C




Panel D

Figures 9C and 9D




A= (-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

Figure 10




Panel A




Panel B

A= (-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4-(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

Figure 11




Panel A




Panel B

Figure 12



Panel A



Panel B

Figure 13






Figure 14



Panel A



Panel B

Figure 15






Figure 16



Panel A



Panel B

Figure 17

5264758v.1